Stereotactic body radiotherapy plus PD-1 inhibitors for advanced non-small-cell lung cancer: a prospective, single-arm, phase 2 trial

Purpose This study aimed to investigate the efficacy and safety of stereotactic body radiotherapy (SBRT) in combination with the PD-1 inhibitor camrelizumab in patients with non-small-cell lung cancer (NSCLC). Patients and methods This prospective, single-arm, phase 2 trial enrolled patients with confirmed driver mutation-negative, stage IV NSCLC and oligometastases (≤5 lesions) at Henan Cancer Hospital. Eligible patients received four to six cycles of first-line chemoimmunotherapy; those with non-progressive disease subsequently received SBRT to the primary tumor or metastatic lesions, followed by consolidation camrelizumab. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and objective response rate (ORR). Safety was assessed in all patients receiving at least one fraction of SBRT. Results Of 48 screened patients, 46 (35 men, 11 women) received SBRT plus camrelizumab and were analyzed. A total of 49 lesions (17 primary, 32 metastatic) were irradiated. The median age was 64 years (range, 36–74), and the median follow-up was 24.4 months. In the full analysis set ( n = 46), the median PFS (mPFS) and OS (mOS) were 13.6 months and 32.9 months, respectively. The 2-year PFS and OS rates were 34.8% and 74.1%, respectively. The ORR was 34.8% (16/46; 95% CI, 21.4%–50.2%). In exploratory subgroup analyses, median PFS was also longer in the primary-tumor SBRT group than in the metastatic-lesion SBRT group (33.1 vs 12.2 months; hazard ratio [HR], 2.37; 95% confidence interval [CI], 1.10–5.11; P = 0.023). Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 6 (13.0%) patients, with reactive cutaneous capillary endothelial proliferation (RCCEP) being the most common TRAE overall (21 patients [46%]). No grade 4 or higher TRAEs occurred. Conclusions Consolidative radiotherapy followed by camrelizumab maintenance was associated with encouraging survival outcomes in selected patients with driver-mutation-negative oligometastatic NSCLC who had non-progressive disease after induction chemoimmunotherapy. However, the single-arm design precludes conclusions regarding a survival benefit or the incremental contribution of radiotherapy. These findings warrant further evaluation in randomized controlled trials. Clinical trial registration https://www.chictr.org.cn , identifier ChiCTR2100050165.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1977088
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Stereotactic body radiotherapy plus PD-1 inhibitors for advanced non-small-cell lung cancer: a prospective, single-arm, phase 2 trial

Hong Ge, Yibo Zhao, Zhuangzhuang Zhang, Nannan Zhang et al.
Frontiers in Immunology
Lung Cancer Diagnosis and Treatment
article

Stereotactic body radiotherapy plus PD-1 inhibitors for advanced non-small-cell lung cancer: a prospective, single-arm, phase 2 trial

Hong Ge, Yibo Zhao, Zhuangzhuang Zhang, Nannan Zhang, Chengcheng Fan, XU Wencai, Xiaoli Zheng, Xiaoran Cao
article en

Abstract

Purpose This study aimed to investigate the efficacy and safety of stereotactic body radiotherapy (SBRT) in combination with the PD-1 inhibitor camrelizumab in patients with non-small-cell lung cancer (NSCLC). Patients and methods This prospective, single-arm, phase 2 trial enrolled patients with confirmed driver mutation-negative, stage IV NSCLC and oligometastases (≤5 lesions) at Henan Cancer Hospital. Eligible patients received four to six cycles of first-line chemoimmunotherapy; those with non-progressive disease subsequently received SBRT to the primary tumor or metastatic lesions, followed by consolidation camrelizumab. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and objective response rate (ORR). Safety was assessed in all patients receiving at least one fraction of SBRT. Results Of 48 screened patients, 46 (35 men, 11 women) received SBRT plus camrelizumab and were analyzed. A total of 49 lesions (17 primary, 32 metastatic) were irradiated. The median age was 64 years (range, 36–74), and the median follow-up was 24.4 months. In the full analysis set ( n = 46), the median PFS (mPFS) and OS (mOS) were 13.6 months and 32.9 months, respectively. The 2-year PFS and OS rates were 34.8% and 74.1%, respectively. The ORR was 34.8% (16/46; 95% CI, 21.4%–50.2%). In exploratory subgroup analyses, median PFS was also longer in the primary-tumor SBRT group than in the metastatic-lesion SBRT group (33.1 vs 12.2 months; hazard ratio [HR], 2.37; 95% confidence interval [CI], 1.10–5.11; P = 0.023). Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 6 (13.0%) patients, with reactive cutaneous capillary endothelial proliferation (RCCEP) being the most common TRAE overall (21 patients [46%]). No grade 4 or higher TRAEs occurred. Conclusions Consolidative radiotherapy followed by camrelizumab maintenance was associated with encouraging survival outcomes in selected patients with driver-mutation-negative oligometastatic NSCLC who had non-progressive disease after induction chemoimmunotherapy. However, the single-arm design precludes conclusions regarding a survival benefit or the incremental contribution of radiotherapy. These findings warrant further evaluation in randomized controlled trials. Clinical trial registration https://www.chictr.org.cn , identifier ChiCTR2100050165.

Frontiers in ImmunologyVol. 17
Zhengzhou University (CN), Henan Cancer Hospital (CN)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon